| 货号 | 14879-5mg |
| 描述 | Overactivity of the epidermal growth factor receptor-associated tyrosine kinase (EGFR) has been associated with cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread.1 PD 153035 is a highly potent, reversible inhibitor of the EGFR (Ki = 5.2 pM; IC50 = 29 pM).2 It has been shown to rapidly suppress autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells, as well as to selectively block EGF-mediated cellular processes, including mitogenesis and early gene expression.3,4 |
| 别名 | AG-1517; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Ciardiello, F. and Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer Res. 7(10), 2958-2970 (2001). 2.Fry, D.W.,Kraker, A.J.,McMichael, A., et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265(5175), 1093-1095 (1994). 3.Bos, M.,Mendelsohn, J.,Kim, Y.M., et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clinical Cancer Research 3(11), 2099-2106 (1997). 4.Rae, J.M. and Lippman, M.E. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Research and Treatment 83(2), 99-107 (2004). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 396.7 |
| 分子式 | C16H14BrN3O2 • HCl |
| CAS号 | 183322-45-4 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |